NewLink Genetics Corporation: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei NewLink Genetics Corporation listata cu simbolul US.NLNK ==Descriere companie== Lumos Pharma Inc (www.newlinkgenetics.com) is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, is in late-stage clinical development for the treatment of Pediatric Growth Hormone Def...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Lumos Pharma Inc (www.newlinkgenetics.com) is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, is in late-stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). | Lumos [[PHARMA|Pharma]] Inc (www.newlinkgenetics.com) is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, is in late-stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== |
Versiunea curentă din 2 octombrie 2024 10:23
Pagina dedicata companiei NewLink Genetics Corporation listata cu simbolul US.NLNK
Descriere companie[edit | ]
Lumos Pharma Inc (www.newlinkgenetics.com) is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, is in late-stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD).
Grafic actiuni companie[edit | ]